Placebo News and Research

RSS

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011

Caffeine may predict risk of drug abuse

Parents of young caffeine consumers take heed: that high-calorie energy drink or soda might present more than just obesity risk. In fact, according to a double-blind, placebo-controlled study that examined responses to stimulants, an individual's subjective response to caffeine may predict how he or she will respond to other stimulant drugs, possibly reflecting differences in risk for abuse of other more serious drugs of abuse, such as amphetamine and cocaine.

10 Oct 2011

Teriflunomide drug reduces relapse rate of people with MS

A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease.

7 Oct 2011

Orexigen presents data from Contrave trial at 29th Annual Scientific Meeting of The Obesity Society

Orexigen Therapeutics, Inc., today announced that Contrave (naltrexone SR/bupropion SR) data will be presented in one oral and multiple poster presentations at the 29th Annual Scientific Meeting of The Obesity Society on October 3, 2011 in Orlando, FL.

4 Oct 2011

PE, CT appear to reduce PTSD symptoms in patients with recent traumatic event

Prolonged exposure therapy, cognitive therapy, and delayed prolonged exposure therapy, appear to reduce posttraumatic stress disorder symptoms in patients who have experienced a recent traumatic event, according to a report published Online First by Archives of General Psychiatry, one of the JAMA/Archives journals.

4 Oct 2011

Quick injection of cortisone can prevent PTSD

As soldiers return home from tours in Afghanistan and Iraq, America must cope with the toll that war takes on mental health. But the treatment of Post Traumatic Stress Disorder (PTSD) is becoming increasingly expensive, and promises to escalate as yet another generation of veterans tries to heal its psychological wounds.

4 Oct 2011

Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies, today announced the Company will report new clinical data results from the miravirsen Phase 2a proof-of-concept study to treat patients infected with the Hepatitis C virus (HCV) in a late-breaking oral presentation session at the American Association for the Study of Liver Diseases (AASLD) 2011 annual meeting.

4 Oct 2011

AMRI announces final results from ALB-127158(a) Phase I clinical studies on obesity

AMRI announced today the final results from its Phase I clinical studies on its novel MCH1 receptor antagonist, ALB-127158(a) during the 29th Annual Scientific Meeting of the Obesity Society in Orlando, Fla.

4 Oct 2011

Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy

Sangamo BioSciences, Inc. today announced that its Phase 2b study (SB-509-901) did not meet its primary or secondary clinical endpoints in subjects with moderate severity diabetic neuropathy (DN) as compared to placebo.

3 Oct 2011

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Boehringer Ingelheim Canada and Eli Lilly Canada today announced that Health Canada has approved Trajenta (linagliptin), a new oral therapy to improve glycemic control in Canadian adults with type 2 diabetes.

3 Oct 2011

Alkermes initiates ALKS 37 phase 2b study in opioid-induced constipation

Alkermes plc today announced the initiation of a phase 2b study of ALKS 37, an orally active, peripherally restricted opioid antagonist for the treatment of opioid-induced constipation.

3 Oct 2011

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Pfizer Inc. today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis, a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.

1 Oct 2011

Researchers identify protein-based blood biomarkers in patients treated with EPO

Biomarkers in the bloodstream could provide a rapid assessment of therapeutic intervention in ischemic stroke and allow patient stratification

1 Oct 2011

Cincinnati Children's to conduct first medication clinical trial for pediatric migraine

Cincinnati Children's Hospital Medical Center has received a $12 million grant from the National Institutes of Health to conduct the first clinical trial to determine the medication of choice for preventing migraines in children and teens.

30 Sep 2011

Array announces results from selumetinib Phase 2 combination study on KRAS-mutant NSCLC

Array BioPharma Inc. today announced results from a randomized Phase 2 placebo-controlled study conducted by AstraZeneca comparing the efficacy of selumetinib in combination with docetaxel with docetaxel alone in the second-line treatment of 87 patients prospectively selected with KRAS-mutant, locally advanced or metastatic non-small cell lung cancer.

30 Sep 2011

VDC and P.A.D. Coalition present annual research awards at VDF's eighth annual meeting

The Venous Disease Coalition (VDC) and Peripheral Arterial Disease Coalition presented their annual research awards at the Vascular Disease Foundation's eighth annual meeting in Washington.

30 Sep 2011

Microbicide Trials Network stops tenofovir arm of study after findings show drug less effective than anticipated

"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, on Wednesday announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports.

30 Sep 2011

AstraZeneca settles SEROQUEL XR patent infringement litigation

AstraZeneca today announced it has entered into a settlement agreement in its U.S. SEROQUEL XR patent infringement litigation against Handa Pharmaceuticals, LLC regarding Handa's proposed generic version of AstraZeneca's SEROQUEL XR extended-release tablets.

30 Sep 2011

Powerful HIV vaccine being tested on humans

Spanish researchers have developed a prototype of a vaccine against the AIDS-causing HIV virus that is “much more powerful” than those made to date.

29 Sep 2011

Bulgaria’s decades old anti-smoking pill could be a cheap and effective answer to smoking cessation

A pill from Bulgaria during the Soviet era shows promise for helping millions of smokers cheaply and safely kick the habit, the first big clinical trial of it shows. It is unclear whether it will ever reach the market in the U.S. or Western Europe though.

29 Sep 2011

Placebo News and Research

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Caffeine may predict risk of drug abuse

Teriflunomide drug reduces relapse rate of people with MS

Orexigen presents data from Contrave trial at 29th Annual Scientific Meeting of The Obesity Society

PE, CT appear to reduce PTSD symptoms in patients with recent traumatic event

Quick injection of cortisone can prevent PTSD

Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV

AMRI announces final results from ALB-127158(a) Phase I clinical studies on obesity

Sangamo's SB-509 fails to meet key endpoints in Phase 2b study for diabetic neuropathy

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Alkermes initiates ALKS 37 phase 2b study in opioid-induced constipation

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Researchers identify protein-based blood biomarkers in patients treated with EPO

Cincinnati Children's to conduct first medication clinical trial for pediatric migraine

Array announces results from selumetinib Phase 2 combination study on KRAS-mutant NSCLC

VDC and P.A.D. Coalition present annual research awards at VDF's eighth annual meeting

Microbicide Trials Network stops tenofovir arm of study after findings show drug less effective than anticipated

AstraZeneca settles SEROQUEL XR patent infringement litigation

Powerful HIV vaccine being tested on humans

Bulgaria’s decades old anti-smoking pill could be a cheap and effective answer to smoking cessation

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News